FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211918493> ?p ?o ?g. }

• W3211918493 abstract "The objective of this study was to examine the expression of Nischarin (NISCH) in pancreatic ductal adenocarcinoma (PDAC), and its potential as a target for drug repurposing. NISCH has been described as a tumor suppressor in breast and ovarian cancers, and there are several clinically approved agonists for this receptor. NISCH has also been reported as a scaffolding protein with a role in cell adhesion, invasion and metabolism – aspects of the PDAC biology that are of interest for therapeutical intervention. We examined mRNA and protein expression of NISCH in publicly available datasets, patient tumor samples, representative PDAC cell lines and patient-derived stellate cells. We found that NISCH is a prognostic marker in PDAC patients and that it is expressed in both cancer cells and cancer-associated stroma. Gene set enrichment analysis showed that NISCH expression was associated with the regulation of cell motility, cell cycle and energy metabolism. Indeed, NISCH knockdown in cancer cells induced reorganization of the actin cytoskeleton. Next, we tested the effects of three clinically approved NISCH agonists (rilmenidine, clonidine and moxonidine) on cancer cells and cancer-associated fibroblasts (CAFs). We found that rilmenidine, agonist with the highest affinity for the NISCH receptor, had the most potent effect. Rilmenidine impaired cancer cell adhesion, limited migration and decreased production of pro-metastatic cytokines and extracellular matrix deposition in cancer cell-CAF co-cultures. Our study lays a ground for more extensive examination of the role of NISCH in PDAC and implies that NISCH agonists may be good candidates for drug repurposing in this type of cancer.Citation Format: Jelena Grahovac, Marijana Pavlovic, Marija Ostojic, Kristina Zivic, Daniel Galun, Tatjana Srdic-Rajic. Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-040." @default.
• W3211918493 created "2021-11-22" @default.
• W3211918493 creator A5011749534 @default.
• W3211918493 creator A5049064278 @default.
• W3211918493 creator A5059611364 @default.
• W3211918493 creator A5063794011 @default.
• W3211918493 creator A5067051468 @default.
• W3211918493 creator A5073275864 @default.
• W3211918493 date "2021-11-15" @default.
• W3211918493 modified "2023-10-03" @default.
• W3211918493 title "Abstract PO-040: Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing" @default.
• W3211918493 doi "https://doi.org/10.1158/1538-7445.panca21-po-040" @default.
• W3211918493 hasPublicationYear "2021" @default.
• W3211918493 type Work @default.
• W3211918493 sameAs 3211918493 @default.
• W3211918493 citedByCount "0" @default.
• W3211918493 crossrefType "proceedings-article" @default.
• W3211918493 hasAuthorship W3211918493A5011749534 @default.
• W3211918493 hasAuthorship W3211918493A5049064278 @default.
• W3211918493 hasAuthorship W3211918493A5059611364 @default.
• W3211918493 hasAuthorship W3211918493A5063794011 @default.
• W3211918493 hasAuthorship W3211918493A5067051468 @default.
• W3211918493 hasAuthorship W3211918493A5073275864 @default.
• W3211918493 hasConcept C121608353 @default.
• W3211918493 hasConcept C126322002 @default.
• W3211918493 hasConcept C170493617 @default.
• W3211918493 hasConcept C2779013556 @default.
• W3211918493 hasConcept C2780210213 @default.
• W3211918493 hasConcept C502942594 @default.
• W3211918493 hasConcept C56219504 @default.
• W3211918493 hasConcept C71924100 @default.
• W3211918493 hasConcept C86803240 @default.
• W3211918493 hasConcept C96232424 @default.
• W3211918493 hasConcept C98274493 @default.
• W3211918493 hasConceptScore W3211918493C121608353 @default.
• W3211918493 hasConceptScore W3211918493C126322002 @default.
• W3211918493 hasConceptScore W3211918493C170493617 @default.
• W3211918493 hasConceptScore W3211918493C2779013556 @default.
• W3211918493 hasConceptScore W3211918493C2780210213 @default.
• W3211918493 hasConceptScore W3211918493C502942594 @default.
• W3211918493 hasConceptScore W3211918493C56219504 @default.
• W3211918493 hasConceptScore W3211918493C71924100 @default.
• W3211918493 hasConceptScore W3211918493C86803240 @default.
• W3211918493 hasConceptScore W3211918493C96232424 @default.
• W3211918493 hasConceptScore W3211918493C98274493 @default.
• W3211918493 hasLocation W32119184931 @default.
• W3211918493 hasOpenAccess W3211918493 @default.
• W3211918493 hasPrimaryLocation W32119184931 @default.
• W3211918493 hasRelatedWork W2058903925 @default.
• W3211918493 hasRelatedWork W2283698778 @default.
• W3211918493 hasRelatedWork W2346074809 @default.
• W3211918493 hasRelatedWork W2356126442 @default.
• W3211918493 hasRelatedWork W2582912872 @default.
• W3211918493 hasRelatedWork W2968996136 @default.
• W3211918493 hasRelatedWork W3033478340 @default.
• W3211918493 hasRelatedWork W4220845808 @default.
• W3211918493 hasRelatedWork W4283771460 @default.
• W3211918493 hasRelatedWork W4304116770 @default.
• W3211918493 isParatext "false" @default.
• W3211918493 isRetracted "false" @default.
• W3211918493 magId "3211918493" @default.
• W3211918493 workType "article" @default.